Jerry Avorn


Columbia Journalism Review–The Complicity of the Media in Drug Marketing Wed, 27 Jul 2005 An excellent article in the Columbia Journalism Review examines pharmaceutical industry hype and the media’s role in helping that industry create false impressions about the safety and benefits of newly marketed drugs: “stories trumpeting new drugs […]

Columbia Journalism Review–The Complicity of the Media in Drug Marketing


Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the many questionable non-medical income-producing activities that America┬╣s physicians […]

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash ...


At FDA, Changes In Name Only–Agency Puts Business interests Above Safety Fri, 30 Sep 2005 The sudden resignation of FDA Commissioner, Lester Crawford, after just two months in office, has prompted a bipartisan Senate investigation and requests both by the Senate committee HELP and by congressman Maurice Hinchey (NY) and […]

At FDA, Changes In Name Only–Agency Puts Business interests Above ...



FDA Standards – Good Enough for Government Work? Fri, 23 Sep 2005 An essay in The New England Journal of Medicine, by Jerry Avorn, M.D., professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, chalolenges FDA’s “minimalist” drug […]

FDA Standards – Good Enough for Government Work?


Safety of American Drugs Questioned – Assoc Press Thu, 2 Dec 2004 In his CNN news program last evening, Lou Dobbs said the question is no longer whether something is wrong with the FDA’s performance in protecting the public from unsafe drugs–but whether the FDA can even be salvaged? The […]

Safety of American Drugs Questioned – Assoc Press


FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to the FDA, the agency’s focus changed from safety […]

FDA Is Flexing Less Muscle where Safety is the Issue ...